





Kite Pharma: summary of recent CAR-T/IO business alliances/deals

Company	Partner	Date	Area	Details
	Daiichi-Sankyo	9 th Jan 2017	Axicabtagene ciloleucel in Japan	Option to license additional Kite candidates including KITE-718*, \$50m upfront, \$200m milestones plus double digit royalties
	Fosun Pharma	10 th Jan 2017	Axicabtagene ciloleucel in China. Possibly KITE-439/718 [§]	Upfront \$20m & \$40m to Kite. 60:40 profit split. Milestones \$35m
	Genentech	17 th March 2017	Clinical collaboration for KTE-C19 and atezolizumab (anti-PDL1 antibody)	A multi-center Phase 1b/2 study was expected to begin in 2016 of which Kite now sponsors
	Cell Design Labs	2 nd June 2016	Next generation, precision-controlled chimeric antigen receptor (CAR) product candidates "on off" switches	Kite pays CDL upfront and additional payments. CDL eligible to receive royalties on product sales. Kite increased equity investment


*KITE-718 is a TCR product candidate targeting MAGE-A3/A6

^Amgen can receive a similar amount on their candidates

§ Opt-in and milestone payments for KITE-439 and KITE-718 could total \$140 million plus profit sharing and mid-single digit sales royalties

IO = immuno-oncology

Kite Pharma: summary of recent CAR-T/IO business alliances/deals

Company	Partner	Date	Area	Details
 Kite Pharma	Amgen	5 th Jan 2015	Next generation novel CAR immunotherapies Based on eACT™ platform	Kite received \$60m upfront, R&D funding through IND filing. Eligible for \$525m milestones [^] , tiered royalties

[^]Amgen can receive a similar amount on their candidates

IO = immuno-oncology

About iOnco Analytics:

iOnco Analytics is a subdivision of VacZine Analytics, a world leading supplier of vaccine market analyses

With our product lines:

- ① MarketVIEW
- ① ExpertREACT


Our role is to define market potential and strategy of new cancer immunotherapies

Disclaimer

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.





iOnco Analytics

Immunotherapeutic market strategy...

www.iOnco-analytics.com

Carlton House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

Tel +44 (0) 1279 813155

E-mail: info@ionco-analytics.com